Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "2025年12月29日至2026年1月2日603290股价走势预测"

Looking for quality documents?
external link icon
Repligen Reports Second Quarter 2018 Financial Results
Record quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “Our second quarter financial performance was led by record direct sales of our filtration and chromatography products, which nearly doubled year-over-year and delivered greater than 25% organic growth. Our Spectrum products continue to perform well, with 29% pro forma growth over the second quarter of 2017. In our Proteins franchise, we
external link icon
Repligen To Present at 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing-focused company delivering technology innovation to improve biologic drug manufacturing flexibility and efficiency, today announced that the Company will be presenting at the 36 th Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2018 in San Francisco. Tony J. Hunt, President and CEO of Repligen, will present a company overview on Tuesday, January 9 at 4:00 p.m. PT. 
A live webcast of the event will be accessible through the Investor Relations section of Repligen’s website. This webcast will be archived for a period of time following the live event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein
external link icon
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 in shares of its common stock in connection with the proposed public offering. All shares of common stock will be offered by Repligen Corporation. Repligen Corporation expects to use the net proceeds to fund the cash portion of the purchase price for its previously announced proposed acquisition of C Technologies, Inc. and for working capital and other general corporate purposes. J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the
external link icon
Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
Waltham, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands at Repligen’s facilities in Waltham, MA and Lund, Sweden. Repligen is the main strategic supplier of Protein A ligands to Purolite, an emerging player in the Protein A resin market with its Praesto® line of modern agarose-based, high-flow chromatography resins. Pursuant to the agreement, Repligen will supply Protein A ligands to Purolite through November 2022, with an option for renewal through 2025. Protein A chromatography remains the gold standard for monoclonal antibody purification, consistently providing outstanding results.  Steve Tingley, VP of Sales for Repligen said, “We are delighted that Purolite has made the decision to extend our current supply agreement, which ensures the supply of high quality Protein A ligands to Purolite for the next five to eight
external link icon
Repligen to Report First Quarter 2016 Financial Results
WALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 financial results on Thursday, May 5, 2016. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended March 31, 2016.
The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 97934207. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 97934207. About Repligen
external link icon
Repligen to Report Second Quarter 2015 Financial Results
WALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report second quarter 2015 financial results on Thursday, August 6, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended June 30, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers or (404) 537-3372 for international callers. Dial-in participants must provide the passcode 91950805. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 91950805. About Repligen Corporation Repligen
external link icon
Repligen to Report First Quarter 2015 Financial Results
WALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2015 financial results on Thursday, May 7, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting period ended March 31, 2015. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers or (404) 537-3372 for international callers. Dial-in participants must provide the passcode 34417361. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 34417361. About Repligen Corporation Repligen
external link icon
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “ Advancing Impacts ”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2023 Sustainability Report are detailed disclosures aligned with four key reporting frameworks: the Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs) and Task Force on Climate-Related Disclosures (TCFD). Olivier Loeillot, President and Chief Executive Officer at Repligen said, “I am delighted with the progress we’ve made
external link icon
Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 40th Annual J.P. Morgan Healthcare conference being held January 10-13.  Tony J. Hunt, President and Chief Executive Officer, will present on Wednesday, January 12, 2022, at 9:45 a.m. EST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract
external link icon
Repligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference
WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 10th Annual SVB Leerink Healthcare conference being held February 22-26.  Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, February 26, at 12:00 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support